Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Blood (2024) 144 (15): 1595–1610.

https://doi.org/10.1182/blood.2023022884

Published: 2024

Includes: Supplemental data

Journal Articles

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Henan Zhang, MD, Shulan Tian, Esteban Braggio, PhD, Andrew L Feldman, MD, Rhett P. Ketterling, MD, Rong He, MD, Timothy G. Call, MD, Thomas E. Witzig, MD, Sameer A. Parikh, MD, Yi Lin, MD PhD, Charla R Secreto, Emma I Andersson, MSc, Satu Mustjoki, MD PhD, Alexandra Schrader, Marco Herling, MD PhD, Huihuang Yan, Ph. D, Wei Ding, MD PhD

Blood (2016) 128 (22): 4103.

https://doi.org/10.1182/blood.V128.22.4103.4103

Published: 2016

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)

Natali Pflug, MD, Georg Hopfinger, MD, Paula Cramer, MD, Alexandra Schrader, PhD, Nicole Weit, PhD, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, MD, Thorsten Zenz, MD, Jan Duerig, MD, Jasmin Bahlo, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Anna-Maria Fink, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Marco Herling, MD

Blood (2014) 124 (21): 1999.

https://doi.org/10.1182/blood.V124.21.1999.1999

Published: 2014

Journal Articles

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

Mark J. Kiel, Thirunavukkarasu Velusamy, Delphine Rolland, Anagh A. Sahasrabuddhe, Fuzon Chung, Nathanael G. Bailey, Alexandra Schrader, Bo Li, Jun Z. Li, Ayse B. Ozel, Bryan L. Betz, Roberto N. Miranda, L. Jeffrey Medeiros, Lili Zhao, Marco Herling, Megan S. Lim, Kojo S. J. Elenitoba-Johnson

Blood (2014) 124 (9): 1460–1472.

https://doi.org/10.1182/blood-2014-03-559542

Published: 2014

Includes: Supplemental data

Journal Articles

Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas

Katerina Vrzalikova, Martina Vockerodt, Sarah Leonard, Andrew Bell, Wenbin Wei, Alexandra Schrader, Kenneth L. Wright, Dieter Kube, Martin Rowe, Ciaran B. Woodman, Paul G. Murray

Blood (2011) 117 (22): 5907–5917.

https://doi.org/10.1182/blood-2010-09-307710

Published: 2011

Includes: Supplemental data

NARROW

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas

Email alerts

ASH Publications

American Society of Hematology

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only